Aura Biosciences (NASDAQ:AURA) Posts Earnings Results, Beats Expectations By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) issued its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Down 3.5 %

AURA traded down $0.36 during trading on Thursday, hitting $9.97. The company had a trading volume of 115,587 shares, compared to its average volume of 175,237. The firm’s 50-day moving average price is $9.75 and its 200 day moving average price is $8.50. The company has a market capitalization of $494.61 million, a PE ratio of -5.81 and a beta of 0.33. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AURA. BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. JMP Securities increased their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Scotiabank increased their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday. Finally, Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at approximately $1,615,340.28. The trade was a 15.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. This represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,259 shares of company stock valued at $780,699 in the last 90 days. 5.40% of the stock is currently owned by company insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.